מכירות החברה talis.bio (TLIS)

Talis Biomedical (TLIS) is currently pivoting its business model, preserving assets to monetize its proprietary software. Demand for such rapid tests remains stable even during crises, particularly in winter. The company's commercial sales metric reflects the current cash inflow rate, with the value fixed at 0.00. Efficiency is maintained through outsourced electronics manufacturing and international reagent logistics.

For Talis Biomedical (TLIS), whose defensive market barriers have been neutralized by delisting and the cessation of operations, operating cash flow is virtually exhausted. This indicator aggregates daily revenue from the sale of diagnostic systems, allowing investors to assess financial stability and the consistency of inflows, while the company's sales statistics clearly demonstrate a critical decline in the issuer's commercial activity.